ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2011
Cognitive control deficits in schizophrenia: mechanisms and meaning.
Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03061136 (Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia), which is not on this map. Cited by 274 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia
Who cites it
274 citing papers in PubMed, 6 syntheses or guidelines pooled it, 510 citations in OpenAlex.
- A systematic review on dysconnectivity in face and emotion processing networks in schizophrenia.Cognitive, affective & behavioral neuroscience · 2026Pooled it
- Functional brain abnormalities of cognitive impairments in schizophrenia indicating higher integration of working memory than other domains.Molecular psychiatry · 2026Pooled it
- Unraveling consistently altered brain activations of language deficits in schizophrenia: evidence from ALE meta-analysis.Translational psychiatry · 2025Pooled it
- A Systematic Review of the Human Accelerated Regions in Schizophrenia and Related Disorders: Where the Evolutionary and Neurodevelopmental Hypotheses Converge.International journal of molecular sciences · 2023Pooled it
- Cortical control of chandelier cells in neural codes.Frontiers in cellular neuroscience · 2022Pooled it
- Association of Schizotypy With Dimensions of Cognitive Control: A Meta-Analysis.Schizophrenia bulletin · 2018Pooled it
- Real-time fMRI neurofeedback modulates auditory cortex activity and connectivity in schizophrenia patients with auditory hallucinations: A controlled study.Psychiatry research. Neuroimaging · 2025Trial
- Altered brainstem responses to modafinil in schizophrenia: implications for adjunctive treatment of cognition.Translational psychiatry · 2018Trial
- Tolcapone-Enhanced Neurocognition in Healthy Adults: Neural Basis and Predictors.The international journal of neuropsychopharmacology · 2017Trial
- Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study.Psychological medicine · 2016Trial
- Sustained Modafinil Treatment Effects on Control-Related Gamma Oscillatory Power in Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Trial
- An fMRI-Based Neural Signature of Decisions to Smoke Cannabis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
- Ketamine-Induced Modulation of the Thalamo-Cortical Network in Healthy Volunteers As a Model for Schizophrenia.The international journal of neuropsychopharmacology · 2015Trial
- Impacted and preserved sub-domains of cognitive control in schizophrenia.Neuropsychologia · 2026Article
- NMDA receptor ablation in medial prefrontal cortex disrupts value updating and reward history integration.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Modeling decision dynamics disentangles working memory, cognitive control and reinforcement learning and reveals clinical differences.PLoS computational biology · 2026Article
- The Relationship between Air Pollution Exposure, Genetic Liability for Schizophrenia, and Brain Outcomes in the ABCD Study.Schizophrenia bulletin · 2026Article
- Reading between the lines: Combining pause dynamics and semantic coherence for automated assessment of thought disorder.Neuropsychologia · 2026Article
- Volume and Tempo: Cortical Excitability and Trial-to-Trial Consistency of Auditory Responses Distinguish Psychosis Biotypes.Research square · 2026Article
- Shared subcortical-default mode morphological dysconnectivity in adolescent bipolar disorder, major depressive disorder and schizophrenia.Communications biology · 2026Article
214 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Although schizophrenia is an illness that has been historically characterized by the presence of positive symptomatology, decades of research highlight the importance of cognitive deficits in this disorder. This review proposes that the theoretical model of cognitive control, which is based on contemporary cognitive neuroscience, provides a unifying theory for the cognitive and neural abnormalities underlying higher cognitive dysfunction in schizophrenia. To support this model, we outline converging evidence from multiple modalities (eg, structural and functional neuroimaging, pharmacological data, and animal models) and samples (eg, clinical high risk, genetic high risk, first episode, and chronic subjects) to emphasize how dysfunction in cognitive control mechanisms supported by the prefrontal cortex contribute to the pathophysiology of higher cognitive deficits in schizophrenia. Our model provides a theoretical link between cellular abnormalities (eg, reductions in dentritic spines, interneuronal dysfunction), functional disturbances in local circuit function (eg, gamma abnormalities), altered inter-regional cortical connectivity, a range of higher cognitive deficits, and symptom presentation (eg, disorganization) in the disorder. Finally, we discuss recent advances in the neuropharmacology of cognition and how they can inform a targeted approach to the development of effective therapies for this disabling aspect of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.